BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung Cancer

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2022-10-31

Last Posted Date: 2023-12-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT05599685

Locations: 🇬🇷
Local Institution - 0001, Athens, Greece

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

Phase 3

Active, not recruiting

Conditions: Cardiomyopathy, Hypertrophic

Interventions: Drug: Mavacamten
Other: Placebo

First Posted Date: 2022-10-17

Last Posted Date: 2024-10-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 420

Registration Number: NCT05582395

Locations: 🇦🇺
Local Institution - 0078, Milton, Queensland, Australia
🇦🇺
Local Institution - 0050, Bedford Park, South Australia, Australia
🇦🇺
Local Institution - 0076, Murdoch, Western Australia, Australia

and more 222 locations

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986322
Drug: Loestrin

First Posted Date: 2022-10-14

Last Posted Date: 2023-08-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 42

Registration Number: NCT05579574

Locations: 🇺🇸
Local Institution - 0001, Anaheim, California, United States
🇺🇸
Local Institution - 0002, Anaheim, California, United States

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: MORAb-202

First Posted Date: 2022-10-13

Last Posted Date: 2024-11-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT05577715

Locations: 🇺🇸
Rocky Mountain Cancer Centers - Lone Tree, Lone Tree, Colorado, United States
🇺🇸
Clermont Oncology Center, Clermont, Florida, United States
🇺🇸
Mid Florida Cancer Center - Orange City, Orange City, Florida, United States

and more 26 locations

A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.

Phase 2

Recruiting

Conditions: Beta-thalassemia

Interventions: Drug: Placebo
Drug: Luspatercept

First Posted Date: 2022-10-05

Last Posted Date: 2024-08-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 90

Registration Number: NCT05567458

Locations: 🇨🇳
Local Institution - 0002, Maoming, Guangdong, China
🇨🇳
Local Institution - 0005, Shenzhen, Guangdong, China
🇨🇳
Local Institution - 0007, Liuzhou, Guangxi, China

and more 7 locations

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986369

First Posted Date: 2022-10-05

Last Posted Date: 2023-02-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT05567510

Locations: 🇺🇸
Labcorp Clinical Research Unit - Madison, Madison, Wisconsin, United States

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Phase 2

Active, not recruiting

Conditions: Cardiomyopathy, Hypertrophic

Interventions: Drug: MYK-224

First Posted Date: 2022-09-27

Last Posted Date: 2024-07-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT05556343

Locations: 🇺🇸
Local Institution - 0014, Los Angeles, California, United States
🇺🇸
Local Institution - 0016, San Francisco, California, United States
🇺🇸
Local Institution - 0026, La Jolla, California, United States

and more 22 locations

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Phase 2

Terminated

Conditions: Alopecia Areata

Interventions: Drug: Deucravacitinib
Other: Placebo

First Posted Date: 2022-09-27

Last Posted Date: 2024-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 94

Registration Number: NCT05556265

Locations: 🇺🇸
Local Institution - 0013, Houston, Texas, United States
🇵🇱
Local Institution - 0025, Warsaw, Poland
🇺🇸
Local Institution - 0012, Austin, Texas, United States

and more 25 locations

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Phase 3

Recruiting

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Mezigdomide
Drug: Dexamethasone

First Posted Date: 2022-09-23

Last Posted Date: 2024-12-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 525

Registration Number: NCT05552976

Locations: 🇺🇸
USA Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
TOI Clinical Research, Cerritos, California, United States
🇺🇸
Kaiser Permanente - Irvine, Irvine, California, United States

and more 211 locations

A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis

Completed

Conditions: Psoriasis

First Posted Date: 2022-09-21

Last Posted Date: 2023-12-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3506

Registration Number: NCT05547490

Locations: 🇨🇳
Local Institution - 0001, Nanjing, Jiangsu, China
🇨🇳
Local Institution - 0002, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy